Vertex Pharmaceuticals Valuation
Is VRTX * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of VRTX * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: VRTX * (MX$8630.65) is trading below our estimate of fair value (MX$9288.06)
Significantly Below Fair Value: VRTX * is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for VRTX *?
Other financial metrics that can be useful for relative valuation.
What is VRTX *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$122.32b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 10.7x |
Enterprise Value/EBITDA | 23.7x |
PEG Ratio | 2.9x |
Price to Earnings Ratio vs Peers
How does VRTX *'s PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 72.3x | ||
CSL CSL | 38.4x | 14.7% | AU$142.6b |
REGN Regeneron Pharmaceuticals | 29.4x | 12.3% | US$115.3b |
AMGN Amgen | 44.7x | 18.2% | US$167.8b |
GILD Gilead Sciences | 176.8x | 36.2% | US$86.4b |
VRTX * Vertex Pharmaceuticals | 30.3x | 10.4% | Mex$122.3b |
Price-To-Earnings vs Peers: VRTX * is good value based on its Price-To-Earnings Ratio (30.3x) compared to the peer average (72.3x).
Price to Earnings Ratio vs Industry
How does VRTX *'s PE Ratio compare vs other companies in the Global Biotechs Industry?
Price-To-Earnings vs Industry: VRTX * is expensive based on its Price-To-Earnings Ratio (30.3x) compared to the Global Biotechs industry average (29.1x).
Price to Earnings Ratio vs Fair Ratio
What is VRTX *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 30.3x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate VRTX *'s Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | Mex$8,630.65 | Mex$8,580.63 -0.6% | 12.8% | Mex$10,573.06 | Mex$5,955.37 | n/a | 29 |
Jun ’25 | Mex$7,488.30 | Mex$7,864.06 +5.0% | 12.5% | Mex$9,789.21 | Mex$5,513.85 | n/a | 28 |
May ’25 | Mex$6,735.00 | Mex$7,912.32 +17.5% | 12.2% | Mex$9,879.17 | Mex$5,593.61 | n/a | 29 |
Apr ’25 | Mex$6,957.00 | Mex$7,694.31 +10.6% | 12.4% | Mex$9,578.22 | Mex$5,423.21 | n/a | 29 |
Mar ’25 | Mex$7,222.00 | Mex$7,874.71 +9.0% | 12.6% | Mex$9,864.49 | Mex$5,546.65 | n/a | 28 |
Feb ’25 | Mex$7,411.65 | Mex$7,460.47 +0.7% | 13.9% | Mex$9,551.35 | Mex$5,365.16 | n/a | 27 |
Jan ’25 | Mex$6,857.85 | Mex$6,955.01 +1.4% | 11.0% | Mex$8,494.30 | Mex$5,334.42 | n/a | 28 |
Dec ’24 | Mex$6,035.53 | Mex$6,869.52 +13.8% | 9.2% | Mex$7,912.42 | Mex$5,448.47 | n/a | 28 |
Nov ’24 | Mex$6,394.95 | Mex$6,891.52 +7.8% | 9.4% | Mex$8,122.41 | Mex$5,593.06 | n/a | 28 |
Oct ’24 | Mex$6,110.00 | Mex$6,701.32 +9.7% | 9.3% | Mex$7,948.54 | Mex$5,473.33 | n/a | 27 |
Sep ’24 | Mex$5,869.00 | Mex$6,462.15 +10.1% | 9.4% | Mex$7,668.55 | Mex$5,280.54 | n/a | 27 |
Aug ’24 | Mex$5,828.00 | Mex$6,404.17 +9.9% | 9.9% | Mex$7,688.75 | Mex$5,159.56 | n/a | 27 |
Jul ’24 | Mex$5,962.00 | Mex$6,424.25 +7.8% | 9.3% | Mex$7,806.49 | Mex$5,238.57 | n/a | 27 |
Jun ’24 | Mex$5,682.00 | Mex$6,571.97 +15.7% | 10.0% | Mex$8,052.87 | Mex$5,386.24 | Mex$7,488.30 | 28 |
May ’24 | Mex$6,162.00 | Mex$6,046.01 -1.9% | 9.5% | Mex$7,870.66 | Mex$5,020.01 | Mex$6,735.00 | 26 |
Apr ’24 | Mex$5,646.80 | Mex$6,221.49 +10.2% | 9.5% | Mex$8,193.24 | Mex$5,213.88 | Mex$6,957.00 | 26 |
Mar ’24 | Mex$5,394.30 | Mex$6,154.62 +14.1% | 9.7% | Mex$8,146.82 | Mex$5,184.34 | Mex$7,222.00 | 26 |
Feb ’24 | Mex$5,893.71 | Mex$6,181.92 +4.9% | 10.3% | Mex$8,258.45 | Mex$5,255.38 | Mex$7,411.65 | 26 |
Jan ’24 | Mex$5,592.00 | Mex$6,294.15 +12.6% | 10.8% | Mex$8,554.48 | Mex$5,152.13 | Mex$6,857.85 | 25 |
Dec ’23 | Mex$6,125.00 | Mex$6,294.15 +2.8% | 10.8% | Mex$8,554.48 | Mex$5,152.13 | Mex$6,035.53 | 25 |
Nov ’23 | Mex$6,221.34 | Mex$6,349.41 +2.1% | 10.8% | Mex$8,716.20 | Mex$5,225.77 | Mex$6,394.95 | 25 |
Oct ’23 | n/a | Mex$6,188.31 0% | 10.9% | Mex$7,765.33 | Mex$4,990.58 | Mex$6,110.00 | 25 |
Sep ’23 | Mex$5,795.00 | Mex$6,172.05 +6.5% | 10.9% | Mex$7,742.93 | Mex$4,976.18 | Mex$5,869.00 | 25 |
Aug ’23 | Mex$5,500.00 | Mex$6,152.42 +11.9% | 12.1% | Mex$7,492.85 | Mex$4,886.64 | Mex$5,828.00 | 24 |
Jul ’23 | Mex$5,790.36 | Mex$6,031.07 +4.2% | 12.2% | Mex$7,543.52 | Mex$4,919.69 | Mex$5,962.00 | 23 |
Jun ’23 | Mex$5,258.02 | Mex$5,792.83 +10.2% | 12.2% | Mex$7,250.89 | Mex$4,728.84 | Mex$5,682.00 | 23 |
Analyst Forecast: Target price is lower than the current share price.